Brief: Xbrane Biopharma Q3 Loss For Period Narrows To SEK 45.5 Mln

Xbrane Biopharma AB

29/10/2021 07:13

Oct 29 (Reuters) - Xbrane Biopharma AB  XBRANE.ST :
    * XBRANE BIOPHARMA RELEASES INTERIM REPORT FOR JANUARY –
SEPTEMBER
2021
    * Q3 REVENUE AMOUNTED TO SEK 0.0M (0.0)
    * Q3 EBITDA WAS SEK -39.5M (-54.2)
    * Q3 LOSS FOR PERIOD WAS SEK -45.5M (-57.7)

Source text for Eikon:  ID:nMFN7P0rVw 
Further company coverage:  XBRANE.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))